Shares of BioNTech Explode 150% Higher on Potential Coronavirus Vaccine

Written by: Michael Harris
April 3, 2020
  • BioNTech, German drugmaker, agrees to cooperate with Pfizer and Shanghai Fosun Pharmaceutical on the potential vaccine for coronavirus
  • Germany is trying to stop its drug makers from moving its research units to United States
  • BioNTech stock price hit an all-time high today of €71.50

BioNTech (NASDAQ:BNTX) stock price skyrocketed higher this week after the company signed a deal with the U.S. drugmaker giant Pfizer (NYSE:PFE) and China’s Shanghai Fosun Pharmaceutical (SS:600196) to work together on the new vaccine for coronavirus.

Fundamental analysis: Vaccine aimed at preventing COVID-19 infection

Drugmaker giant Pfizer and the Germany-based BioNTech signed a letter of intent aimed at co-development and distribution, with the exception of China, of a potential coronavirus vaccine for preventing COVID-19 infection. The collaboration is expected to commence immediately.

Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today.

The deal excludes China as BioNTech yesterday announced a deal with Shanghai Fosun Pharmaceutical over the rights in China for its potential coronavirus vaccine. It is said that testing on humans can start as soon as April.

“We are proud that our ongoing, successful relationship with BioNTech gives our companies the resiliency to mobilize our collective resources with extraordinary speed in the face of this worldwide challenge,” said Mikael Dolsten, Chief Scientific Officer at Pfizer, in a joint press release.

The two companies are planning to finalize the development details and financial terms over the next few weeks. Development teams will be using sites in both Germany and the United States, during the process.

“This is a global pandemic, which requires a global effort. In joining forces with our partner Pfizer, we believe we can accelerate our effort to bring a COVID-19 vaccine to people around the world who need it,” said Ugur Sahin, Co-Founder and CEO of BioNTech.

This announcement comes just two days after Germany acted to stop the U.S. Government from working to move CureVac, another German drugmaker, to the United States. The company is allegedly also working on the coronavirus vaccine.

Tip: looking for an app to invest wisely? Trade safely by signing-up with our preferred choice, eToro: visit & create account

Technical analysis: Price explodes higher

Shares of BioNTech exploded higher over the past two days after the German drugmaker announced agreements with Pfizer and Shanghai Fosun Pharmaceutical. The price shot from the mid €20s to over €70 in just three days.

BioNTech stock daily chart (TradingView)

As seen in the chart, the price action was capped by the ascending trend line (the red line) around the €70 mark. It is hard to project higher levels as the price action trades in uncharted territory. As a reference, the previous all-time high was €44.66, printed in January, which is 37% lower than today’s high of €71.50.


Shares of BioNTech exploded higher after the company announced deals with Pfizer and Shanghai Fosun Pharmaceutical to work together on the potential coronavirus vaccine. As a result, the stock price rose more than 150% in just three days.